In the same way that estrogen receptor staining has been standardized, and is widely available at most centers, we recommend that ultra‐sensitive estradiol quantitation should also be clinically available and routinely utilized for breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.